Literature DB >> 19018454

Analysis of factors affecting increase in bone mineral density at lumbar spine by bisphosphonate treatment in postmenopausal osteoporosis.

Hiroshi Kaji1, Itoko Hisa, Yoshifumi Inoue, Junko Naito, Toshitsugu Sugimoto, Masato Kasuga.   

Abstract

Bisphosphonate is an effective drug to reduce fracture risk in osteoporotic patients; however, factors affecting the efficacy of bisphosphonate treatment are not fully known, especially in Japanese patients. In the present study, we examined the relationships between an increase in lumbar spine bone mineral density (BMD) by bisphosphonates and several pretreatment parameters, including biochemical, bone/mineral, and body composition indices, in 85 postmenopausal osteoporotic patients treated with alendronate or risedronate. BMD increase was measured by dual-energy X-ray absorptiometry at the lumbar spine before and 2 years after treatment. BMD increase at the lumbar spine was observed as independent of age, height, weight, body mass index, and fat mass, although lean body mass seemed slightly related. On the other hand, fasting plasma glucose (FPG) levels were significantly and positively related to BMD increase at the lumbar spine. In multiple regression analysis, FPG levels were not significantly related to BMD increase at the lumbar spine when lean body mass was considered. As for bone/mineral parameters, BMD increase at the lumbar spine was not significantly related to serum levels of calcium, parathyroid hormone (PTH), and alkaline phosphatase or urinary levels of deoxypiridinoline and calcium excretion. As for BMD parameters, Z-scores of BMD at any site and bone geometry parameters obtained by forearm peripheral quantitative computed tomography were not significantly related to BMD increase at the lumbar spine. BMD increases at the lumbar spine were similar between groups with or without vertebral fractures. In conclusion, BMD increase at the lumbar spine by bisphosphonate treatment was not related to any pretreatment parameters, including body size, body composition, and bone/mineral metabolism in postmenopausal Japanese women with primary osteoporosis, although FPG correlated partly to BMD through lean body mass.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19018454     DOI: 10.1007/s00774-008-0005-y

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  34 in total

1.  Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004).

Authors:  Hajime Nawata; Satoshi Soen; Ryoichi Takayanagi; Ikuko Tanaka; Kunio Takaoka; Masao Fukunaga; Toshio Matsumoto; Yasuo Suzuki; Hiroyuki Tanaka; Saeko Fujiwara; Takami Miki; Akira Sagawa; Yoshiki Nishizawa; Yoshiki Seino
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

2.  Bone mineral density in adults with the metabolic syndrome: analysis in a population-based U.S. sample.

Authors:  Mitsuyo Kinjo; Soko Setoguchi; Daniel H Solomon
Journal:  J Clin Endocrinol Metab       Date:  2007-09-04       Impact factor: 5.958

3.  Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.

Authors:  Nelson B Watts; Piet Geusens; Ian P Barton; Dieter Felsenberg
Journal:  J Bone Miner Res       Date:  2005-08-08       Impact factor: 6.741

4.  Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.

Authors:  Sophie A Jamal; Douglas C Bauer; Kristine E Ensrud; Jane A Cauley; Marc Hochberg; Areef Ishani; Steven R Cummings
Journal:  J Bone Miner Res       Date:  2007-04       Impact factor: 6.741

5.  Determinants of bone mineral density and spinal fracture risk in postmenopausal Japanese women.

Authors:  D Nakaoka; T Sugimoto; H Kaji; M Kanzawa; S Yano; M Yamauchi; T Sugishita; K Chihara
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

6.  Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women.

Authors:  P Mezquita-Raya; M Muñoz-Torres; J D Luna; V Luna; F Lopez-Rodriguez; E Torres-Vela; F Escobar-Jiménez
Journal:  J Bone Miner Res       Date:  2001-08       Impact factor: 6.741

7.  Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women.

Authors:  K K Nicodemus; A R Folsom
Journal:  Diabetes Care       Date:  2001-07       Impact factor: 19.112

8.  Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.

Authors:  Marc C Hochberg; Susan Greenspan; Richard D Wasnich; Paul Miller; Desmond E Thompson; Philip D Ross
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

9.  Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.

Authors:  J A Kanis; I P Barton; O Johnell
Journal:  Osteoporos Int       Date:  2004-07-23       Impact factor: 4.507

10.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

View more
  9 in total

1.  A high fat diet-induced impaired glucose metabolism in mice with targeted deletion of calpain in osteoblasts.

Authors:  Aki Kashiwagi; Mikaela J Fein; Masako Shimada
Journal:  Biochem Biophys Res Commun       Date:  2011-05-05       Impact factor: 3.575

2.  Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism.

Authors:  Mathieu Ferron; Jianwen Wei; Tatsuya Yoshizawa; Andrea Del Fattore; Ronald A DePinho; Anna Teti; Patricia Ducy; Gerard Karsenty
Journal:  Cell       Date:  2010-07-23       Impact factor: 41.582

3.  Fasting plasma glucose levels are related to bone mineral density in postmenopausal women with primary hyperparathyroidism.

Authors:  Itoko Hisa; Hiroshi Kaji; Yoshifumi Inoue; Toshitsugu Sugimoto; Kazuo Chihara
Journal:  Int J Clin Exp Med       Date:  2008-09-22

4.  Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study.

Authors:  H Kaji; Y Kuroki; Y Murakawa; I Funakawa; Y Funasaka; F Kanda; T Sugimoto
Journal:  Osteoporos Int       Date:  2009-11-17       Impact factor: 4.507

5.  Effect of parathyroid hormone on hypogonadism induced bone loss of proximal femur of orchiectomized rat.

Authors:  M Tezval; G Serferaz; T Rack; L Kolios; S Sehmisch; U Schmelz; H Tezval; K M Stuermer; E K Stuermer
Journal:  World J Urol       Date:  2011-02-05       Impact factor: 4.226

6.  Influence of treatment with alendronate on the speed of sound, an ultrasound parameter, of the calcaneus in postmenopausal Japanese women with osteoporosis: a clinical practice-based observational study.

Authors:  Jun Iwamoto; Tetsuya Takada; Yoshihiro Sato; Hideo Matsumoto
Journal:  Ther Clin Risk Manag       Date:  2012-06-20       Impact factor: 2.423

7.  An NMR metabolomic study on the effect of alendronate in ovariectomized mice.

Authors:  Shin-Yu Chen; Hui-Tzu Yu; Ju-Po Kao; Chung-Chun Yang; Shen-Shih Chiang; Darya O Mishchuk; Jeng-Leun Mau; Carolyn M Slupsky
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

Review 8.  Menopause care for obese and diabetic women.

Authors:  J Verhaeghe
Journal:  Facts Views Vis Obgyn       Date:  2009

9.  The effects of metformin and alendronate in attenuating bone loss and improving glucose metabolism in diabetes mellitus mice.

Authors:  Qiyun Zhou; Zhiqiang Guan; Shengfu Liu; Yanjiao Xuan; Gang Han; Hua Chen; Xiao Jin; Kun Tao; Zhiyuan Guan
Journal:  Aging (Albany NY)       Date:  2022-01-14       Impact factor: 5.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.